These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21411794)

  • 1. FDA seeks advice on track-and-trace systems.
    Traynor K
    Am J Health Syst Pharm; 2011 Apr; 68(7):552-4. PubMed ID: 21411794
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA embraces RFID to protect drug supply.
    Young D
    Am J Health Syst Pharm; 2004 Dec; 61(24):2612, 2615. PubMed ID: 15646694
    [No Abstract]   [Full Text] [Related]  

  • 3. US drug shortages are set to reach record high in 2011, report says.
    Tanne JH
    BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406
    [No Abstract]   [Full Text] [Related]  

  • 4. Systems-based approach to risk management.
    Menighan TE
    J Am Pharm Assoc (2003); 2005; 45(2):116. PubMed ID: 15868747
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA increases focus on postmarketing studies.
    Goozner M
    J Natl Cancer Inst; 2010 Sep; 102(17):1302-4. PubMed ID: 20739650
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 8. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.
    Weaver J; Willy M; Avigan M
    AAPS J; 2008; 10(1):35-41. PubMed ID: 18446503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Workshop Report: Crystal City VI-Bioanalytical Method Validation for Biomarkers.
    Arnold ME; Booth B; King L; Ray C
    AAPS J; 2016 Nov; 18(6):1366-1372. PubMed ID: 27514862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IOM panel hears concerns about U.S. drug safety system.
    Young D
    Am J Health Syst Pharm; 2005 Jul; 62(14):1428, 1430-31. PubMed ID: 15998915
    [No Abstract]   [Full Text] [Related]  

  • 11. Advancing Product Quality: a Summary of the Second FDA/PQRI Conference.
    Yu LX; Akseli I; Allen B; Amidon G; Bizjak TG; Boam A; Caulk M; Doleski D; Famulare J; Fisher AC; Furness S; Hasselbalch B; Havel H; Hoag SW; Iser R; Johnson BD; Ju R; Katz P; Lacana E; Lee SL; Lostritto R; McNally G; Mehta M; Mohan G; Nasr M; Nosal R; Oates M; O'Connor T; Polli J; Raju GK; Ramanadham M; Randazzo G; Rosencrance S; Schwendeman A; Selen A; Seo P; Shah V; Sood R; Thien MP; Tong T; Trout BL; Tyner K; Vaithiyalingam S; VanTrieste M; Walsh F; Wesdyk R; Woodcock J; Wu G; Wu L; Yu L; Zezza D
    AAPS J; 2016 Mar; 18(2):528-43. PubMed ID: 26860627
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing the impact of developments in micro-instrumentation on process analytical technology: a consortium approach.
    Koch MV
    Anal Bioanal Chem; 2006 Mar; 384(5):1049-53. PubMed ID: 16049668
    [No Abstract]   [Full Text] [Related]  

  • 13. Bad medicine. Monitoring programs target substandard drugs.
    Grens K
    Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275
    [No Abstract]   [Full Text] [Related]  

  • 14. Reporting drug product defects--JCAHO.
    Hoffmann RP
    Hosp Pharm; 1989 Feb; 24(2):143-4. PubMed ID: 10318199
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 16. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA--a misunderstood agency.
    Sharfstein JM
    JAMA; 2011 Sep; 306(11):1250-1. PubMed ID: 21934058
    [No Abstract]   [Full Text] [Related]  

  • 18. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA post-marketing safety decisions.
    Klein DF
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.
    Kenny JR; Liu MM; Chow AT; Earp JC; Evers R; Slatter JG; Wang DD; Zhang L; Zhou H
    AAPS J; 2013 Oct; 15(4):933-40. PubMed ID: 23794076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.